Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline
results from three Phase III trials evaluating the efficacy, safety and
tolerability of vilazodone in adult patients with generalized anxiety
disorder (GAD). In two flexible-dose and one fixed-dose GAD trials,
patients who received vilazodone demonstrated statistically significant
improvement from baseline in the Hamilton Rating Scale for Anxiety
(HAM-A) total score versus placebo at week 8, the primary endpoint.
- Following intra-articular injection, sustained release of triamcinolone acetonide ( TCA) from FX006 maintained therapeutic concentration levels in knee joints of patients through 12 weeks -
- Pharmacokinetic (PK) data support previously completed Phase 2b dose-ranging efficacy trial that demonstrated superior magnitude and duration of pain relief over 12 weeks compared to current standard of care -
BURLINGTON, Mass., June 17, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks.
Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study
Data Submitted for Presentation at Medical Meeting Later this Year REDWOOD CITY, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.